Fidelity Investments
LYEL icon

Fidelity Investments’s Lyell Immunopharma LYEL Stock Holding History

Fidelity Investments’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.6K Sell
1,823
-6
-0.3% -$140 ﹤0.01% 4256
2025
Q4 		$56.3K Sell
1,829
-893
-33% -$20K ﹤0.01% 4045
2025
Q3 		$44.2K Sell
2,722
-355
-12% -$4.05K ﹤0.01% 4031
2025
Q2 		$27.2K Buy
3,077
+2,110
+218% +$19.2K ﹤0.01% 4165
2025
Q1 		$10.4K Buy
967
+162
+20% +$1.99K ﹤0.01% 4480
2024
Q4 		$10.3K Sell
805
-50,424
-98% -$1,000K ﹤0.01% 4459
2024
Q3 		$1.41M Sell
51,229
-85,444
-63% -$2.51M ﹤0.01% 2502
2024
Q2 		$3.96M Sell
136,673
-1,790
-1% -$85.2K ﹤0.01% 2151
2024
Q1 		$6.18M Sell
138,463
-973
-0.7% -$41.7K ﹤0.01% 2026
2023
Q4 		$5.41M Sell
139,436
-2,935
-2% -$106K ﹤0.01% 2038
2023
Q3 		$4.19M Sell
142,371
-851
-0.6% -$40.4K ﹤0.01% 2092
2023
Q2 		$9.11M Sell
143,222
-3,288
-2% -$182K ﹤0.01% 1897
2023
Q1 		$6.92M Sell
146,510
-2,059
-1% -$110K ﹤0.01% 2002
2022
Q4 		$10.3M Sell
148,569
-16,162
-10% -$1.61M ﹤0.01% 1873
2022
Q3 		$24.1M Buy
164,731
+24,654
+18% +$3.34M ﹤0.01% 1549
2022
Q2 		$18.3M Buy
140,077
+15,961
+13% +$1.63M ﹤0.01% 1687
2022
Q1 		$12.5M Buy
124,116
+70,993
+134% +$8.6M ﹤0.01% 2023
2021
Q4 		$8.22M Buy
53,123
+34,158
+180% +$7.62M ﹤0.01% 2194
2021
Q3 		$5.61M Buy
18,965
+6,605
+53% +$1.98M ﹤0.01% 2325
2021
Q2 		$4.01M Buy
+12,360
New +$4.05M ﹤0.01% 2398

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments's LYEL Position: Q1 2026 in Review

Fidelity Investments reduced its Lyell Immunopharma (LYEL) stake by 0.33% in Q1 2026, selling an estimated $140 and leaving 1,823 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4256.

Fidelity Investments first reported a position in LYEL in Q2 2021 and has held it in 20 quarters since. The position peaked at $24.1M in Q3 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Fidelity Investments held 1,823 shares of Lyell Immunopharma worth $36.6K as of Q1 2026.
  • Fidelity Investments sold 6 Lyell Immunopharma shares in Q1 2026, an estimated $140.
  • Lyell Immunopharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4256 holding.
  • Fidelity Investments first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 20 quarters since.
  • Fidelity Investments's Lyell Immunopharma position peaked at $24.1M in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.